FDA's Janet Woodcock says the flood of breakthrough therapy designations is probably not an anomaly and is a result of the increased number of targeted therapies that present dramatic efficacy in early clinical trials.

Speaking on BioCentury This Week television, Woodcock said many breakthroughs, especially in cancer, could be stepping stones to the ultimate goal, durable remissions and cures (see BioCentury This Week, June 23).